Microbix BiosystemsMBXBF 55 3-Year RORE % is 2,550.00 as of Mar. 2026. GuruFocus rates MBXBF with a GF Score™ of 55/100 and a GF Value™ of $0.18 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,290 Biotechnology companies, Microbix Biosystems ranks worse than 77519.3% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Microbix Biosystems's 3-Year RORE % for the quarter that ended in Mar. 2026 was 2,550.00%.
The industry rank for Microbix Biosystems's 3-Year RORE % or its related term are showing as below:
MBXBF's 3-Year RORE % is not ranked
in the Biotechnology industry.
Industry Median: -11.54
vs MBXBF: 2550.00
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Microbix Biosystems 3-Year RORE % Related Terms
Microbix Biosystems 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBXBF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Microbix Biosystems's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Microbix Biosystems (MBXBF) has a 3-Year RORE % of 2,550.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #999999 out of 1290 companies in the Biotechnology industry.
Is Microbix Biosystems' 3-Year RORE % too high?
Microbix Biosystems' current 3-Year RORE % is 2,550.00. Based on the distribution chart, Microbix Biosystems ranks #999999 out of 1290 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Microbix Biosystems has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #999999 out of 1290 companies for 3-Year RORE %. This places Microbix Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current 3-Year RORE % is 2,550.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.18, compared to a current price of $0.22 — trading 19.9% above its estimated fair value. The current 3-Year RORE % is 2,550.00. Microbix Biosystems' overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current 3-Year RORE % is 2,550.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 19.9% above its estimated GF Value™ of $0.18.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
3-Year RORE %: 2,550.00
GF Value™: $0.18 vs. price of $0.22 (19.9% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
55GF Score
Get the complete analysis for MBXBF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
